Case report: Multi-organ injuries induced by tislelizumab

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 4, 2025

The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report case induced by tislelizumab in lung squamous cell carcinoma (LUSC) patient. A 68-year-old man had undergone neoadjuvant chemotherapy with paclitaxel, carboplatin, and tislelizumab. He presented 1-month history nausea poor appetite after the second dose therapy. During investigations, rhabdomyolysis, liver, kidney, thyroid damage were detected. After multi-disciplinary consultation, related to ICIs (striated muscle, thyroid) considered result from cumulated irAEs patient was treated levothyroxine, methylprednisolone, intravenous immunoglobulins, continuous renal replacement treatment, recovered discharged hospital. multiple organ damage, not single immunity treatment reactions, relatively rare. In clinical work, are likely single-system disorder many kinds attention need be combined risk multi-system damage.

Language: Английский

Immunotherapy in gestational trophoblastic neoplasia: advances and future directions

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 11, 2025

Gestational trophoblastic neoplasia (GTN) is a rare but aggressive malignancy that follows normal or aberrant pregnancies. Until the advent of immunotherapy in 2017, surgery and chemotherapy were standard treatment modalities, with remaining cornerstone. However, chemoresistance high-risk disease present significant challenges managing GTN. Recent advancements immunotherapy, particularly immune checkpoint inhibitors (ICIs), have offered new hope for these difficult cases. This review provides comprehensive overview mechanisms underlying ICIs GTN, explores potential synergy combining targeted therapies, such as vascular endothelial growth factor epidermal receptor inhibitors. We also provide an latest evidence on use treating focusing their effectiveness both low- cases, well chemorefractory settings. In addition, we discuss ongoing clinical trials, immune-related adverse events associated ICIs, biomarker-driven approaches, immunosuppressive tumor microenvironments, posed resistance. The future directions, including integration into regimens, personalized based biology, importance fertility preservation young patients conclusion, while remain, represents promising frontier GTN treatment, to improve outcomes more approach care

Language: Английский